IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59326-9.html
   My bibliography  Save this article

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation

Author

Listed:
  • Siqi Chen

    (City of Hope)

  • Yingyu Wang

    (City of Hope National Medical Center)

  • Jessica Dang

    (City of Hope)

  • Nuozi Song

    (City of Hope)

  • Xiaoxin Chen

    (San Francisco
    San Francisco)

  • Jinhui Wang

    (City of Hope)

  • Guo N. Huang

    (San Francisco
    San Francisco)

  • Christine E. Brown

    (City of Hope
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope)

  • Jianhua Yu

    (City of Hope
    City of Hope National Medical Center
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
    City of Hope)

  • Irving L. Weissman

    (Stanford Medicine
    Stanford Medicine)

  • Steven T. Rosen

    (City of Hope National Medical Center
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
    City of Hope)

  • Mingye Feng

    (City of Hope)

Abstract

Macrophage-based cancer cellular therapy has gained substantial interest. However, the capability of engineered macrophages to target cancer heterogeneity and modulate adaptive immunity remains unclear. Here, exploiting the myeloid antibody-dependent cellular phagocytosis biology and phagocytosis checkpoint blockade, we report the enhanced synthetic phagocytosis receptor (eSPR) that integrate FcRγ-driven phagocytic chimeric antigen receptors (CAR) with built-in secreted CD47 blockers. The eSPR engineering empowers macrophages to combat tumor antigen heterogeneity. Transduced by adenoviral vectors, eSPR macrophages are intrinsically pro-inflammatory imprinted and resist tumoral polarization. Transcriptomically and phenotypically, eSPR macrophages elicit a more favorable tumor immune landscape. Mechanistically, eSPR macrophages in situ stimulate CD8 T cells via phagocytosis-dependent antigen cross-presentation. We also validate the functionality of the eSPR system in human primary macrophages.

Suggested Citation

  • Siqi Chen & Yingyu Wang & Jessica Dang & Nuozi Song & Xiaoxin Chen & Jinhui Wang & Guo N. Huang & Christine E. Brown & Jianhua Yu & Irving L. Weissman & Steven T. Rosen & Mingye Feng, 2025. "CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation," Nature Communications, Nature, vol. 16(1), pages 1-20, December.
  • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59326-9
    DOI: 10.1038/s41467-025-59326-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59326-9
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-025-59326-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Omar Khan & Josephine R. Giles & Sierra McDonald & Sasikanth Manne & Shin Foong Ngiow & Kunal P. Patel & Michael T. Werner & Alexander C. Huang & Katherine A. Alexander & Jennifer E. Wu & John Attanas, 2019. "TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion," Nature, Nature, vol. 571(7764), pages 211-218, July.
    2. Helen S. Goodridge & Christopher N. Reyes & Courtney A. Becker & Tamiko R. Katsumoto & Jun Ma & Andrea J. Wolf & Nandita Bose & Anissa S. H. Chan & Andrew S. Magee & Michael E. Danielson & Arthur Weis, 2011. "Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’," Nature, Nature, vol. 472(7344), pages 471-475, April.
    3. Daniel S. Chen & Ira Mellman, 2017. "Elements of cancer immunity and the cancer–immune set point," Nature, Nature, vol. 541(7637), pages 321-330, January.
    4. Nourhan Abdelfattah & Parveen Kumar & Caiyi Wang & Jia-Shiun Leu & William F. Flynn & Ruli Gao & David S. Baskin & Kumar Pichumani & Omkar B. Ijare & Stephanie L. Wood & Suzanne Z. Powell & David L. H, 2022. "Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    5. Kasia Hrecka & Caili Hao & Magda Gierszewska & Selene K. Swanson & Malgorzata Kesik-Brodacka & Smita Srivastava & Laurence Florens & Michael P. Washburn & Jacek Skowronski, 2011. "Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein," Nature, Nature, vol. 474(7353), pages 658-661, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Feng Xie & Xiaoxue Zhou & Peng Su & Heyu Li & Yifei Tu & Jinjin Du & Chen Pan & Xiang Wei & Min Zheng & Ke Jin & Liyan Miao & Chao Wang & Xuli Meng & Hans Dam & Peter Dijke & Long Zhang & Fangfang Zho, 2022. "Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    2. Maria Pouyiourou & Bianca N. Kraft & Timothy Wohlfromm & Michael Stahl & Boris Kubuschok & Harald Löffler & Ulrich T. Hacker & Gerdt Hübner & Lena Weiss & Michael Bitzer & Thomas Ernst & Philipp Schüt, 2023. "Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    3. Aditi Sahu & Kivanc Kose & Lukas Kraehenbuehl & Candice Byers & Aliya Holland & Teguru Tembo & Anthony Santella & Anabel Alfonso & Madison Li & Miguel Cordova & Melissa Gill & Christi Fox & Salvador G, 2022. "In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    4. Shaoshuai Tang & Yunzhi Wang & Rongkui Luo & Rundong Fang & Yufeng Liu & Hang Xiang & Peng Ran & Yexin Tong & Mingjun Sun & Subei Tan & Wen Huang & Jie Huang & Jiacheng Lv & Ning Xu & Zhenmei Yao & Qi, 2024. "Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    5. Alexandra Gyurdieva & Stefan Zajic & Ya-Fang Chang & E. Andres Houseman & Shan Zhong & Jaegil Kim & Michael Nathenson & Thomas Faitg & Mary Woessner & David C. Turner & Aisha N. Hasan & John Glod & Ro, 2022. "Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    6. Moujtaba Y. Kasmani & Paytsar Topchyan & Ashley K. Brown & Ryan J. Brown & Xiaopeng Wu & Yao Chen & Achia Khatun & Donia Alson & Yue Wu & Robert Burns & Chien-Wei Lin & Matthew R. Kudek & Jie Sun & We, 2023. "A spatial sequencing atlas of age-induced changes in the lung during influenza infection," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    7. Mengxue Zhou & Jiaxin Wang & Jiaxing Pan & Hui Wang & Lujia Huang & Bo Hou & Yi Lai & Fengyang Wang & Qingxiang Guan & Feng Wang & Zhiai Xu & Haijun Yu, 2023. "Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    8. Hao Wu & Xiufeng Zhao & Sophia M. Hochrein & Miriam Eckstein & Gabriela F. Gubert & Konrad Knöpper & Ana Maria Mansilla & Arman Öner & Remi Doucet-Ladevèze & Werner Schmitz & Bart Ghesquière & Sebasti, 2023. "Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    9. Rui Liu & Zhi Ji & Xia Wang & Lila Zhu & Jiaqi Xin & Lijun Ma & Jiayu Zhang & Shaohua Ge & Le Zhang & Yuchong Yang & Tao Ning & Ming Bai & Jingjing Duan & Feixue Wang & Yansha Sun & Hongli Li & Ting D, 2025. "Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial," Nature Communications, Nature, vol. 16(1), pages 1-14, December.
    10. Víctor Albarrán-Fernández & Laura Angelats & Julio Delgado & Alena Gros & Álvaro Urbano-Ispizua & Sònia Guedan & Aleix Prat, 2025. "Unlocking the potential of engineered immune cell therapy for solid tumors," Nature Communications, Nature, vol. 16(1), pages 1-5, December.
    11. Emily N. Neubert & Julia M. DeRogatis & Sloan A. Lewis & Karla M. Viramontes & Pedro Ortega & Monique L. Henriquez & Rémi Buisson & Ilhem Messaoudi & Roberto Tinoco, 2023. "HMGB2 regulates the differentiation and stemness of exhausted CD8+ T cells during chronic viral infection and cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    12. Kateryna Onyshchenko & Ren Luo & Elena Guffart & Simone Gaedicke & Anca-Ligia Grosu & Elke Firat & Gabriele Niedermann, 2023. "Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    13. Zhongwei Xin & Mingjie Lin & Zhixing Hao & Di Chen & Yongyuan Chen & Xiaoke Chen & Xia Xu & Jinfan Li & Dang Wu & Ying Chai & Pin Wu, 2022. "The immune landscape of human thymic epithelial tumors," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    14. Han Gao & Sen Li & Zhengyi Lan & Da Pan & Gonna Somu Naidu & Dan Peer & Chenyi Ye & Hangrong Chen & Ming Ma & Zehua Liu & Hélder A. Santos, 2024. "Comparative optimization of polysaccharide-based nanoformulations for cardiac RNAi therapy," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    15. Yi Liu & Brian Debo & Mingfeng Li & Zhennan Shi & Wanqiang Sheng & Yang Shi, 2021. "LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    16. Weicai Huang & Yuming Jiang & Wenjun Xiong & Zepang Sun & Chuanli Chen & Qingyu Yuan & Kangneng Zhou & Zhen Han & Hao Feng & Hao Chen & Xiaokun Liang & Shitong Yu & Yanfeng Hu & Jiang Yu & Yan Chen & , 2022. "Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    17. Leticia Laura Niborski & Paul Gueguen & Mengliang Ye & Allan Thiolat & Rodrigo Nalio Ramos & Pamela Caudana & Jordan Denizeau & Ludovic Colombeau & Raphaël Rodriguez & Christel Goudot & Jean-Michel Lu, 2022. "CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    18. Frank A. Giordano & Julian P. Layer & Sonia Leonardelli & Lea L. Friker & Roberta Turiello & Dillon Corvino & Thomas Zeyen & Christina Schaub & Wolf Müller & Elena Sperk & Leonard Christopher Schmeel , 2024. "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    19. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    20. Tina Sarén & Giulia Saronio & Paula Marti Torrell & Xu Zhu & Josefin Thelander & Yasmin Andersson & Camilla Hofström & Marika Nestor & Anna Dimberg & Helena Persson & Mohanraj Ramachandran & Di Yu & M, 2023. "Complementarity-determining region clustering may cause CAR-T cell dysfunction," Nature Communications, Nature, vol. 14(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59326-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.